LETROZOLEXIN 2.5 - Euro-Pharmacies

Initially launched in 1997 by Novartis under the brand name Femara, Letrozole is a non-steroidal aromatase inhibitor that significantly reduces estrogen levels. It is commonly used as a second-line treatment for estrogen receptor-positive breast cancer, particularly when tamoxifen is ineffective. In the athletic community, letrozole is valued for mitigating estrogenic side effects of anabolic steroids, including gynecomastia and fluid retention. However, prolonged use can impact bone mineral density and cardiovascular health .

Disclaimer: Information provided it this page is for general information only and does not substitute for professional medical advice.

For detailed information about LETROZOLEXIN 2.5 by Euro-Pharmacies, consult with your doctor or healthcare professional.